All News

The FDA has granted APPROVAL for Afamelanotide (Scenesse) for the treatment of Erythropoietic Protoporphyria!

Please consider a donation to the American Porphyria Foundation.

Submissions are being accepted for travel stipends to attend the 2020 Rare Disease Week

5-Year Grant Renewal

The set date for the FDA decision regarding approval of Scenesse is 10 days away.

The ICPP meeting held in Milan, Italy, September 8-11, was a global success!

GPAC has been formalized.

The American Porphyria Foundation hosted a CEP Patient Education and Support Meeting via online webinar.

We are excited to share that Recordati Rare Diseases Canada Inc. announced...

The International Congress on Porphyrins and Porphyrias (ICPP)